An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.

ChemoCentryx, Inc.0 个研究点目标入组 20 人开始时间: 2014年12月29日最近更新: 2018年2月26日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: ChemoCentryx, Inc.
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Biopsy-proven IgAN performed for clinical purposes within 3 years prior to screening
•2. eGRF>60 mL/min/1.73 m² (by MDRD equation) OR eGFR >45 mL/min/1.73 m² if eGFR has not declined < 10 mL/min/1.73 m² over the previous 24 weeks
•3. Proteinuria, defined as first morning urinary PCR > 1g/g creatinine
•4. Male or female subjects, aged at least 18 years; where allowed by local regulations, female subjects of childbearing potential may participate if adequate contraception is used during, and for at least the three months after study completion; male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least the three months after study completion; Adequate contraception is defined as resulting in a failure rate of less than 1% per year (combined estrogen and progestogen (oral, intravaginal, or transdermal), or progestogen-only hormonal contraception (oral, injectable, or implantable), intra-uterine device, intra-uterine hormone releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence)
•5. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
•6. Judged to be otherwise healthy by the Investigator, based on medical history, physical examination, and clinical laboratory assessments. Subjects with clinical laboratory values that are outside of normal limits (other than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance, may be entered into the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 5
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•1. Severe renal disease as determined by rapid decline in eGFR (defined as > 10 mL/min/1.73m² over 24 weeks prior to screening, not otherwise explained)
•2. Pregnant or nursing
•3. Proteinuria > 8 g/day (or>8g/g creatinine)
•4. Patients with systemic manifestations of Henoch-Schönlein purpura within the last 2 years prior to screening.
•5. Patients with IgAN deemed secondary to underlying disease: e.g., diabetes, liver disease, cirrhosis, celiac disease, HIV, inflammatory bowel disease, lymphoma, or associated with any other multi-system autoimmune disease
•6. Biopsy report demonstrating severe crescentic IgAN (>25% crescents), OR>50% interstitial fibrosis and/or tubular atrophy (T2) (Cattran et al. 2009), OR a high likelihood of rapid decline in eGFR based on an MEST (Oxford) classification (M=mesangial hypercellularity; E=endocapillary proliferation; S=segmental glomerulosclerosis/adhesion; T=tubular atrophy/interstitial fibrosis) score of M1, E0, T1, or M0/1, E1, T1 (Cattran et al. 2009)
•7. History of treatment with glucocorticoids, cyclophosphamide, azathioprine, mycophenolate mofetil, or any biologic immunomodulatory agent within the 24 weeks prior to screening
•8. Symptomatic congestive heart failure requiring prescription medication, clinically evident peripheral edema of cardiac origin, poorly-controlled hypertension (systolic blood pressure>160 or diastolic blood pressure >95), history of unstable angina, myocardial infarction or stroke within 6 months prior to screening
•9. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast cacrinoma in situ that has been excised or resected completely and is without evidene of local recurrence or metastasis
•10. Positive HBV, HCV, or HIV viral screening test
•11. History of tuberculosis
•12. Any infection requiring antibiotic treatment that has not cleared prior to starting CCX168 treatment on Day 1;
•13. WBC count less than 4000/uL, or neutrophil count less than 2000/uL, or lymphocyte count less than 1000/uL
•14. Hemoglobin less than 9 g/dL (or 5.56 mmol/L) at screening
•15. Evidence of hepatic disease; AST, ALT, alkaline phosphatase, or bilirubin > 3 x the upper limit of normal
•16. Participated in any clinical study of an investigational product within 30 days prior to screening or within 5 half-lives after taking the last dose
•17. History of presence of any medical condition or disease which, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation

研究者

发起方

ChemoCentryx, Inc.

相似试验

进行中（未招募）

1 期

An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure.MedDRA version: 17.1Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disorders

EUCTR2014-003402-33-BEChemoCentryx, Inc.20

招募中

1 期

Sotatercept in Children with Pulmonary Artery Hypertension on Standard of CareMedDRA version: 21.1Level: LLTClassification code 10037403Term: Pulmonary hypertension NOSSystem Organ Class: 100000004855Pulmonary arterial hypertension

EUCTR2022-000478-25-FRMerck Sharp & Dohme LLC42

进行中（未招募）

1 期

EUCTR2022-000478-25-DEMerck Sharp & Dohme LLC42

进行中（未招募）

1 期

EUCTR2022-000478-25-NLMerck Sharp & Dohme LLC42

进行中（未招募）

1 期

EUCTR2022-000478-25-PLMerck Sharp & Dohme LLC42